Head-To-Head Contrast: Dyadic International (NASDAQ:DYAI) & Enzon Pharmaceuticals (OTCMKTS:ENZN)

Enzon Pharmaceuticals (OTCMKTS:ENZN) and Dyadic International (NASDAQ:DYAI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Institutional and Insider Ownership

28.0% of Dyadic International shares are owned by institutional investors. 0.3% of Enzon Pharmaceuticals shares are owned by insiders. Comparatively, 27.3% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Enzon Pharmaceuticals and Dyadic International’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enzon Pharmaceuticals	$30,000.00	N/A	$1.37 million	$0.01	9.46
Dyadic International	$2.93 million	16.03	-$9.73 million	($0.23)	-7.09

Enzon Pharmaceuticals has higher earnings, but lower revenue than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Enzon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enzon Pharmaceuticals and Dyadic International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enzon Pharmaceuticals	N/A	46.47%	2.92%
Dyadic International	-232.38%	-71.31%	-58.64%

Volatility & Risk

Enzon Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Enzon Pharmaceuticals and Dyadic International, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enzon Pharmaceuticals	0	0	0	0	N/A
Dyadic International	0	0	1	0	3.00

Dyadic International has a consensus target price of $6.00, indicating a potential upside of 268.10%. Given Dyadic International’s higher possible upside, analysts clearly believe Dyadic International is more favorable than Enzon Pharmaceuticals.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design,Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.